Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

Real-time Quote. Real-time Tradegate - 04/29 05:59:56 pm
82.173 EUR   -1.12%
04/28 EMD MILLIPORE : Suit(Ab)le – ChIP and RIP Antibodies
04/26 MERCK KGAA : Introduces First Multi-use Disposable Sterile Connector..
04/26 Merck KGaA Selects Unisys to Deliver Global End-User IT Services ..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Merck KGaA May Withdraw Research from Portugal over Debt-Report

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/09/2012 | 08:28am CEST

German chemical company Merck KGaA (>> Merck KGaA) may withdraw future investments for research projects in Portugal worth tens of millions of euros unless the government hospitals stick to the agreed-upon debt repayments, German daily newspaper Financial Times Deutschland reports Monday.

Merck Portugal's manager Fritz Sacher told the paper the company's research projects are long-term and require mutual trust as a basis. "The Portuguese government's lacking payment habits undermine this trust," he is quoted as saying.

Portuguese government hospitals owe the pharmaceutical industry a total of more than 1.5 billion euros ($1.84 billion) and companies have to wait nearly 550 days on average until invoices are paid, FTD reports.

Some companies, including Roche Holding AG (ROG.VX), have already halted the sale of medications on credit to highly indebted countries like Portugal, Greece, Spain and Italy until outstanding debts are paid, the paper notes, but for many companies such drastic steps are difficult as they carry responsibility for people's wellbeing.

Withdrawing research projects is a way of putting pressure on the government, as Portugal is an attractive location for research investments, FTD says. "The conditions for certain research and human studies are as good as in the U.S., but it's significantly more cost-effective in Portugal," Sacher told the paper.

Newspaper website: http://www.ftd.de

Write to the Frankfurt Bureau at djnews.frankfurt@dowjones.com

Stocks mentioned in the article : Merck KGaA
share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on MERCK KGAA
04/28 MERCK KGAA : New Vinyl Compounds Findings Has Been Reported by Investigators at ..
04/28 REPORTS SUMMARIZE DRUG DEVELOPMENT F : the recent Merck...
04/28 EMD MILLIPORE : Suit(Ab)le – ChIP and RIP Antibodies
04/26 MERCK KGAA : Introduces First Multi-use Disposable Sterile Connectors for Biopha..
04/26 Merck KGaA Selects Unisys to Deliver Global End-User IT Services to Support i..
04/26 MERCK KGAA : Saviynt Selected by the Life Science Business of Merck KGaA, Darmst..
04/25 MERCK KGAA : Wins European Investor Relations Award
04/25 MERCK KGAA : Phase III TAILOR Landmark Study Demonstrates Significant Benefits o..
04/21 MERCK KGAA : EMD Serono to Present Data Assessing Comparative Effectiveness of R..
04/21 JUAN LAMADRID : "San Antonio FC será un equipo combativo"
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials